Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. Dowdy on the Association of Molecular Subtypes and Responses to Bevacizumab in Ovarian Cancer

July 23rd 2014

Sean C. Dowdy, MD, discusses the association of molecular subtypes and responses to bevacizumab in ovarian cancer.

Bevacizumab Receives Priority Review in Ovarian Cancer

July 22nd 2014

The FDA has assigned a priority review designation to bevacizumab (Avastin) in combination with chemotherapy for patients with recurrent platinum-resistant ovarian cancer.

Dr. Hyman on MEDI3617 as Potential Treatment for Patients with Advanced Solid Tumors

July 7th 2014

David Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a phase I study of the selective angiopoietin-2 inhibitor MEDI3617 alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors.

Aggressive Ovarian Cancer Tracked to Inactivating Tumor Mutations

June 30th 2014

Every patient with a rare but aggressive form of ovarian cancer had tumors with the same type of mutations, suggesting a causative role for the mutations.

ODAC Votes Against Maintenance Olaparib in BRCA-Positive Ovarian Cancer

June 25th 2014

The FDA's Oncologic Drugs Advisory Committee voted 11-2 against the accelerated approval of the PARP inhibitor olaparib as a maintenance therapy for women with platinum-sensitive relapsed ovarian cancer with germline BRCA mutations.

Mutations in Ovarian Cancer More Frequent, Varied Than Estimated

June 24th 2014

Genetic testing limited to BRCA1/2 mutations would have missed 29% of mutations that carry hereditary risk of ovarian cancer, a study using next-generation sequencing showed.

PARP Inhibitor Meets Goals in Phase II Ovarian Cancer Trial

June 23rd 2014

One-quarter of patients with relapsed or refractory BRCA-mutant ovarian cancer attained major objective responses to treatment with the investigational PARP inhibitor veliparib.

Dr. Patel on an Analysis of Olaparib and Cediranib for Ovarian Cancer

June 18th 2014

Jyoti D. Patel, MD, discusses a phase II trial that looked at olaparib in combination with cediranib versus olaparib alone in recurrent platinum-sensitive ovarian cancer.

Ovarian Cancer Subtypes May Predict Response to Bevacizumab

June 9th 2014

Sean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.

2014 NCCN Guideline Updates: Experts Highlight New Recommendations for Clinical Practice

June 6th 2014

At the recent National Comprehensive Cancer Network (NCCN) 19th Annual Conference, experts discussed this year's updates to the NCCN Clinical Practice Guidelines in Oncology. The meeting also included reviews of NCCN Task Force reports on issues in supportive care. We asked eleven NCCN panel members to select the most significant updates and insights presented at the conference.

Targeted Therapy Combination Improves PFS in Ovarian Cancer

May 31st 2014

Combining the oral targeted agents olaparib and cediranib resulted in a near-doubling of median progression-free survival (PFS) among women with recurrent ovarian cancer in a phase II study highlighted Saturday during the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.

Irregular Menstruation Linked to Higher Risk of Ovarian Cancer Death

April 9th 2014

A prospective study found that women with irregular menstrual cycles have a 2.4-fold increased risk of dying from ovarian cancer compared to women with normal menstrual cycles

Ellen Matloff on Oophorectomy Timing for BRCA Carriers

March 10th 2014

Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, discusses the proper age for a carrier of the BRCA1 or BRCA2 mutation to undergo oophorectomy.

Integrating Genetic Counseling Into an Oncology Practice Can Benefit High-Risk Families

February 26th 2014

Genetic counseling-including testing and risk assessment-is one of the most rapidly growing areas of oncology and has become the standard of care for patients with a personal and family history of breast, ovary, or colon cancer.

Preventative Ovarian Surgery in BRCA1 Mutation Carriers More Beneficial Before Age 35

February 24th 2014

For the first time, physicians have a clearer understanding of the optimum age for prophylactic oophorectomy in patients with BRCA mutations who want to reduce their risk of ovarian, fallopian tube, and breast cancer.

Dr. Monk on Trial Endpoints For Ovarian Cancer Agents

February 17th 2014

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, on clinical trial endpoints and the approval of agents for ovarian cancer.

Studies Demonstrate Potential of Immunomodulation as Therapeutic Target in Gynecologic Cancers

January 17th 2014

The renaissance in immunology is already affecting treatment paradigms for a variety of gynecologic cancers, and the impact is only likely to expand.

FDA Rules Hamper Novel Ovarian Cancer Drugs

January 7th 2014

The FDA's rules for approving new drugs for the treatment of women with ovarian cancer pose frustrating problems for researchers developing novel agents and for clinicians seeking to improve outcomes for their patients

Dr. Muggia on Doxil in Ovarian Cancer

January 7th 2014

Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses using Doxil to treat ovarian cancer.

Jerry Lanchbury, PhD, Describes Myriad's HRD Test

January 3rd 2014

Jerry Lanchbury, PhD, Chief Scientific Officer, Myriad Genetics, Inc., describes the HRD (homologous recombination deficiency) test.